Intellectual property update confirms pelareorep’s unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional...
Oncolytics Biotech is gaining attention as pelareorep shows encouraging results in multiple cancers, positioning the company as a potentially valuable player in the growing immunotherapy market.
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically...
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial...
Announces that translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American ...
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced translational...
Announced new durability data in metastatic colorectal cancer, demonstrating meaningful and sustained ...
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in...
Announces that a Type C meeting with the U.S. Food and Drug Administration has resulted in alignment ...
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient...